Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer

NCT00005044 is registered in ClinicalTrials.gov with Radiation Therapy Oncology Group as lead sponsor.

NCT NCT00005044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate Cancer
Lead sponsor
Radiation Therapy Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2000
Completion date
May 20, 2022
Enrollment
1,579 (actual)
Sites
261

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer